INSANE: Eli lilly and company - The Real Truth

Eli Lilly and Company Earnings Preview: What to Expect

Eli Lilly and Company is set to report its Q3 results soon, with analysts anticipating single-digit EPS growth alongside continued earnings growth.

Barchart · Oct 14

Rob Lowe Says a Clinical Trial Extended His Grandmother's Life and He Wants Patients Asking Sooner

Rob Lowe describes breast cancer across three generations of his family and argues that patients should ask about clinical trials at diagnosis.

Medical Daily · Sep 2

Vanderbilt Will Build an AI Agent into Medical Records to Cut the Wait for Alzheimer's Infusions

Vanderbilt will build an AI triage agent into its EHR to speed Alzheimer's patients to treatment. What it would do, and who is funding it.

Medical Daily · Aug 7

As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Barchart · Dec 3, 2025

This next-gen weight-loss drug offers a new hope — and a bonus Ozempic and Wegovy don’t have

The once-weekly shot may be a tempting alternative to popular GLP-1 class drugs like Ozempic and Wegovy

The Independent UK · Nov 7, 2025

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times · Oct 30, 2025

3 Dividend Stocks Beating the Market Chaos While Analysts Rate Them a "Strong Buy"

While investors are fleeing the market chaos, these three analyst-backed dividend stocks are quietly surging, with financials too strong to ignore.

Barchart · May 9, 2025

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

Barchart · May 8, 2025

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

StockNews.com · Feb 25, 2025

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

StockNews.com · Nov 29, 2024